MX2016006622A - Metodos para tratar actividad muscular anormal. - Google Patents

Metodos para tratar actividad muscular anormal.

Info

Publication number
MX2016006622A
MX2016006622A MX2016006622A MX2016006622A MX2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A
Authority
MX
Mexico
Prior art keywords
methods
treating abnormal
muscular activity
abnormal muscular
activity
Prior art date
Application number
MX2016006622A
Other languages
English (en)
Inventor
Shah Pratik
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2016006622A publication Critical patent/MX2016006622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Se describen métodos para tratar actividad muscular anormal. Los métodos se pueden realizar de manera remota y permiten el monitoreo de un sujeto fuera de una oficina de un profesional de la salud.
MX2016006622A 2013-11-22 2014-11-21 Metodos para tratar actividad muscular anormal. MX2016006622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907675P 2013-11-22 2013-11-22
PCT/US2014/066740 WO2015077520A1 (en) 2013-11-22 2014-11-21 Methods of treating abnormal muscular activity

Publications (1)

Publication Number Publication Date
MX2016006622A true MX2016006622A (es) 2016-12-09

Family

ID=53180159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006622A MX2016006622A (es) 2013-11-22 2014-11-21 Metodos para tratar actividad muscular anormal.

Country Status (8)

Country Link
US (1) US20160303110A1 (es)
EP (1) EP3071565A4 (es)
JP (1) JP2017503756A (es)
CA (1) CA2930167A1 (es)
HK (1) HK1224294A1 (es)
IL (1) IL245538A0 (es)
MX (1) MX2016006622A (es)
WO (1) WO2015077520A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346800B2 (en) 2012-09-18 2016-05-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
EP2918266A1 (en) * 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EA201791977A1 (ru) 2015-03-06 2018-01-31 Оспекс Фармасьютикалз, Инк. Способы лечения патологических непроизвольных движений
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10786202B2 (en) 2016-09-28 2020-09-29 International Business Machines Corporation Quantifying grip strength and characterizing movement idioms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7367953B2 (en) * 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
WO2007093450A2 (en) * 2006-02-17 2007-08-23 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
KR101429302B1 (ko) * 2006-05-02 2014-08-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 방사성 표지된 디히드로테트라베나진 유도체 및 조영제로서의 이의 용도
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
CN102056541B (zh) * 2008-06-12 2014-09-24 阿密格德勒有限公司 运动机能减退和/或运动机能亢进状态的检测
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
CN102186848B (zh) * 2008-09-18 2014-11-12 奥斯拜客斯制药有限公司 囊泡单胺转运体2的苯并喹啉抑制剂
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
JP2013527237A (ja) * 2010-06-01 2013-06-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド ベンゾキノロン系ｖｍａｔ２阻害剤
WO2012006551A2 (en) * 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
EP2827856A4 (en) * 2012-03-23 2016-03-09 Cardero Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES

Also Published As

Publication number Publication date
EP3071565A4 (en) 2017-08-02
WO2015077520A1 (en) 2015-05-28
HK1224294A1 (zh) 2017-08-18
US20160303110A1 (en) 2016-10-20
EP3071565A1 (en) 2016-09-28
JP2017503756A (ja) 2017-02-02
CA2930167A1 (en) 2015-05-28
IL245538A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2016006622A (es) Metodos para tratar actividad muscular anormal.
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
EP2854940A4 (en) MEDICAL MONITORING AND TREATMENT DEVICE WITH EXTERNAL STIMULATION
ZA201506369B (en) Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness
HK1222778A1 (zh) 醫用裝置及使用該醫用裝置的方法
EP2977008A4 (en) METHOD, DEVICE AND SYSTEM FOR MANUFACTURING A PHANTOM MATCHED TO A PATIENT
EP3050043A4 (en) Monitoring and treating sleep disorders
EP2750761A4 (en) PORTABLE MONITORING AND PROCESSING DEVICE
EP2707079A4 (en) METHOD AND DEVICES FOR DIAGNOSIS, MONITORING OR TREATING MEDICAL SUFFERING FROM OPENING THROUGH A RESPIRATORY WALL
PL2996737T3 (pl) Urządzenie i sposób dostarczania parametrów zabiegu do wykonywania zabiegu u pacjenta
EP2967974A4 (en) SYSTEMS AND METHODS FOR PROVIDING AUTOMATED TITRATION FOR ORAL APPARATUS THERAPY
SG11201509905PA (en) Medical/Care Support Method, Medical/Care Support System, And Medical/ Care Support Program
EP2717758A4 (en) DATA-CAPABLE BAND FOR MEDICAL DIAGNOSTICS, MONITORING AND TREATMENT
HK1218063A1 (zh) 可佩戴式活動監測裝置和相關方法
SG11201508997RA (en) Monitor and system for monitoring living organisms
EP3185942A4 (en) Diagnosis, monitoring, and treatment of respiratory disorders
GB2513585B (en) Data transfer of a heart rate and activity monitor arrangement and a method for the same
EP2942009A4 (en) DIAGNOSTIC AND AUDITORY TREATMENT DEVICE
PL2854870T3 (pl) Sposób i urządzenie do wytwarzania ołowiu 212 do zastosowania medycznego
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
EP2967986A4 (en) OPHTHALMIC TREATMENT DEVICE, SYSTEM AND METHOD OF USE
HK1214752A1 (zh) 由產甲烷菌引起或與之相關的疾病及病狀的診斷、選擇及治療方法
EP2810599A4 (en) METHOD AND SYSTEM FOR ELECTROSTIMULATION FOR THE TREATMENT OF SLEEP APNEA
SG11201508501QA (en) Ecg monitor with an implantable part
SG11201507222WA (en) Non-woven face mask and corresponding cosmetic treatment method.